Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study.
Fong C, Patel B, Peckitt C, Bourmpaki E, Satchwell L, Cromarty S, Kidd S, von Loga K, Uhlik M, Begum R, Rana T, Waddell T, Darby S, Bradshaw A, Roques T, Morgan C, Rees C, Herbertson R, Das P, Thompson C, Hewish M, Petty R, Thistlethwaite F, Rao S, Starling N, Chau I, Cunningham D.
Fong C, et al. Among authors: peckitt c.
ESMO Open. 2024 Jul;9(7):103622. doi: 10.1016/j.esmoop.2024.103622. Epub 2024 Jul 13.
ESMO Open. 2024.
PMID: 39002179
Free PMC article.
Clinical Trial.